Raphael Szalat MD, PhD
Assistant Professor, Hematology & Oncology
820 Harrison Ave | (617) 638-7011rszalat@bu.edu
Biography
I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.
Education
Medicine, MD, Université Paris-Sorbonne, Paris IV
PhD, Université Paris-Sorbonne, Paris IV
Publications
Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
Published on 10/1/2024Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. JAMA Oncol. 2024 Oct 01; 10(10):1362-1369. PMID: 39088206.
Published on 7/1/2024Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024 Jul 01; 109(7):2049-2059. PMID: 38328864.
Published on 5/16/2024Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur MK, Munshi NC. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes. Nat Commun. 2024 May 16; 15(1):4139. PMID: 38755155.
Published on 1/12/2024Kataria Y, Niharika Pillalamarri B, Zirpoli G, Szalat R, Palmer JR, Bertrand KA. Body size and risk of multiple myeloma in the Black Women's Health Study. Br J Cancer. 2024 Mar; 130(5):830-835. PMID: 38212484.
Published on 1/9/2024Bertrand KA, Szalat R. Deciphering racial disparities in multiple myeloma outcomes. Blood Adv. 2024 Jan 09; 8(1):234-235. PMID: 38194241.
Published on 7/27/2023Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 Jul 27; 142(4):313-324. PMID: 37196627.
Published on 6/1/2023Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.
Published on 4/6/2023Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 Apr 06; 141(14):1724-1736. PMID: 36603186.
Published on 11/7/2022Fillmore NR, Szalat RE, La J, Branch-Elliman W, Monach PA, Nguyen V, Samur MK, Brophy MT, Do NV, Munshi NC. Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Natl Acad Sci U S A. 2022 Nov 16; 119(46):e2213783119. PMID: 36343242.